Brought to you by:
VQI study leader highlights virtue of multispecialty gathering of best longitudinal data on PAD procedures
Daniel Bertges, MD, talks to Vascular Specialist about recent findings from his work investigating the IN.PACT Admiral drug-coated balloon (DCB). He related how they showed promising results in treating femoropopliteal in-stent restenosis in a Society for Vascular Surgery (SVS) Vascular…
Paclitaxel DCB performs well in ‘challenging anatomy’ of femoropopliteal in-stent restenosis, VQI registry data show
The IN.PACT Admiral drug-coated balloon (DCB) shows promising results in treating femoropopliteal in-stent restenosis (ISR) in a Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry-based, postmarket surveillance study. This is according to Daniel Bertges, MD, a vascular surgeon…
Disrupt PAD III observational study results confirm safety and effectiveness of IVL in complex calcified lesions
The final 1,373-patient cohort analysis from the Disrupt PAD III observational study (OS) demonstrates consistent intravascular lithotripsy (IVL; Shockwave Medical) outcomes in complex and challenging lesions across multiple peripheral vessel beds. Ehrin Armstrong, MD, from an interventional cardiologist from Adventist…
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated “excellent efficacy and safety” out to 24-month follow-up. This is according to Kenneth Rosenfield, MD, from Massachusetts General Hospital in Boston, who presented the new data at Vascular…
New analysis: Four multicenter trials support primary use of drug-coated balloons over bare metal stents in femoropopliteal lesions
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicenter trials support the primary use of drug-coated balloons (DCBs) versus bare metal stents (BMS) in moderately complex femoropopliteal lesions, new data show. Lead researcher Mehdi Shishehbor, DO,…
‘Excellent’ three-year results presented for the BioMimics 3D stent in longer lesions
At the 2022 Vascular Interventional Advances (VIVA) meeting (Oct. 31–3 Nov. 3), Michael Lichtenberg, MD, from Arnsberg Clinic, Arnsberg, Germany, reported a subgroup analysis of the MIMICS-3D EU registry, revealing a headline finding of “excellent” three-year outcomes for the BioMimics…